Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

BACKGROUND: Despite the success of immune checkpoint blockade therapy in the treatment of certain cancer types, only a small percentage of patients with solid malignancies achieve a durable response. Consequently, there is a need to develop novel approaches that could overcome mechanisms of tumor re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Horn, Lucas A, Riskin, Jeffrey, Hempel, Heidi A, Fousek, Kristen, Lind, Hanne, Hamilton, Duane H, McCampbell, Kristen K, Maeda, Dean Y, Zebala, John A, Su, Zhen, Schlom, Jeffrey, Palena, Claudia
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078948/
https://ncbi.nlm.nih.gov/pubmed/32188703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000326
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados